(continued)
- FDA Expands Approved Use of Vonvendi
- Dawnzera: First RNA-Targeted Therapy to Prevent Hereditary Angioedema Attacks
- FDA Approves Wegovy as First Once-Weekly Injection for Obesity-Linked Liver Disease
- FDA Approves New Non-Opioid, Once-Daily Bedtime Tablet for Fibromyalgia Pain and Sleep Disturbance
- Papzimeos: First Approved Immunotherapy for Recurrent Respiratory Papillomatosis in Adults
- Alhemo: A New Daily Injection to Help Prevent Bleeding in Hemophilia A and B
- Vizz: New Daily Eye Drop to Improve Age-Related Blurry Near Vision
- Empaveli: A New Treatment Option for Rare Immune-Related Kidney Diseases
- Skytrofa Approved as Once-Weekly Option for Adults With Growth Hormone Deficiency
- New Oral Treatment for Adults and Children With Phenylketonuria: Sephience
- New Oral Option for Children With Low Platelet Counts: Doptelet